Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism.

Fish oil polyunsaturated fatty acids and fibrate hypolipidemic drugs are potent hypotriglyceridemic agents that act by increasing fatty acid catabolism and decreasing triglyceride synthesis and secretion by the liver. A major unresolved issue is whether this hypotriglyceridemic effect can occur independent of induction of peroxisomal beta-oxidation, a predisposing factor for hepatocarcinogenesis. The present study was undertaken to determine which component of fish oil, eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), is responsible for its triglyceride-lowering effect. We demonstrate that EPA and not DHA is the hypotriglyceridemic component of fish oil and that mitochondria and not peroxisomes are the principal target. Results obtained by fenofibrate feeding support the hypothesis that the mitochondrion is the primary site for the hypotriglyceridemic effect. In contrast to fibrates, EPA did not affect hepatic apolipoprotein C-III gene expression. Therefore, increased mitochondrial beta-oxidation with a concomitant decrease in triglyceride synthesis and secretion seems to be the primary mechanism underlying the hypotriglyceridemic effect of EPA and fibrates in rats, rabbits and possibly also in humans. In addition, these data show that lowering of plasma triglycerides can occur independently of any deleterious peroxisome proliferation.

[1]  J. Reddy,et al.  Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens , 1980, Nature.

[2]  P. Weber,et al.  Cardiovascular effects of N-3 fatty acids. , 1988, Journal of nutritional science and vitaminology.

[3]  J. Kinsella,et al.  Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. , 1990, The American journal of clinical nutrition.

[4]  H. E. Worne,et al.  EFFECTS OF CERTAIN PURE LONG CHAIN POLYUNSATURATED FATTY ACID ESTERS ON THE BLOOD LIPIDS OF MAN: PRELIMINARY STUDIES ON THE USE OF POLYUNSATURATED FATTY ACIDS IN ATHEROSCLEROSIS , 1959, The American journal of the medical sciences.

[5]  L. Frøyland,et al.  Tetradecylthioacetic acid incorporated into very low density lipoprotein: changes in the fatty acid composition and reduced plasma lipids in cholesterol-fed hamsters. , 1995, Journal of lipid research.

[6]  A. Soutar.  Does dietary fat influence plasma lipoprotein structure? , 1978, Nature.

[7]  J. Lillehaug,et al.  Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. , 1988, British Journal of Cancer.

[8]  W. Connor,et al.  Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. , 1991, The American journal of clinical nutrition.

[9]  M. Connock,et al.  A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. , 1985, The Biochemical journal.

[10]  J. Dyerberg,et al.  Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. , 1971, Lancet.

[11]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[12]  R. Berge,et al.  Docosahexaenoic Acid Shows No Triglyceride- Lowering Effects but Increases the Peroxisomal Fatty Acid Oxidation in Liver of Rats , 2022 .

[13]  G. Mannaerts,et al.  Comparison of the activities of some peroxisomal and extraperoxisomal lipid-metabolizing enzymes in liver and extrahepatic tissues of the rat. , 1985, The Biochemical journal.

[14]  M. Sugano,et al.  alpha-Linolenic, eicosapentaenoic and docosahexaenoic acids affect lipid metabolism differently in rats. , 1994, The Journal of nutrition.

[15]  W. Kunau,et al.  Degradation of Unsaturated Fatty Acids , 1978 .

[16]  Reddy Jk,et al.  Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans , 1983 .

[17]  S. Azen,et al.  Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.

[18]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[19]  K. Bønaa,et al.  Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromsø study. , 1990, The New England journal of medicine.

[20]  J. Kinsella,et al.  Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. , 1992, Biochimica et biophysica acta.

[21]  G. Mannaerts,et al.  Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. , 1979, The Journal of biological chemistry.

[22]  G. Blane,et al.  Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. , 1987, The American journal of medicine.

[23]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[24]  D. McTavish,et al.  Fenofibrate , 2012, Drugs.

[25]  W. Jones,et al.  The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. , 1987, Drug metabolism reviews.

[26]  J. Auwerx,et al.  Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. , 1989, Journal of lipid research.

[27]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[28]  R. Berge,et al.  Morphologic effects of sulfur-substituted fatty acids on rat hepatocytes with special reference to proliferation of peroxisomes and mitochondria. , 1990, Journal of structural biology.

[29]  R. Davis,et al.  Intrahepatic assembly of very low density lipoproteins. Effect of fatty acids on triacylglycerol and apolipoprotein synthesis. , 1982, The Journal of biological chemistry.

[30]  W. Kunau,et al.  Degradation of unsaturated fatty acids. Identification of intermediates in the degradation of cis-4-decenoly-CoA by extracts of beef-liver mitochondria. , 1978, European journal of biochemistry.

[31]  K. Bjerve,et al.  The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. , 1993, Biochimica et biophysica acta.

[32]  H. Lobeck,et al.  Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. , 1983, Atherosclerosis.

[33]  J. Bremer,et al.  The effect of fasting on the activity of liver carnitine palmitoyltransferase and its inhibition by malonyl-CoA. , 1981, Biochimica et biophysica acta.

[34]  J. Reddy,et al.  Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. , 1983, Critical reviews in toxicology.

[35]  J. Shepherd.  The fibrates in clinical practice: focus on micronised fenofibrate. , 1994, Atherosclerosis.

[36]  K. Carlson.  Lipoprotein fractionation. , 1973, Journal of clinical pathology. Supplement.

[37]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[38]  S. Innami,et al.  Differential effects of dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of triglyceride and cholesterol levels in the serum of rats on hypercholesterolemic diet. , 1984, Journal of nutritional science and vitaminology.

[39]  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[40]  J. Bar-Tana,et al.  Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. , 1995, The Journal of Biological Chemistry.

[41]  C Kemmer,et al.  Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. , 1983, Atherosclerosis.

[42]  S. Green.  PPAR: a mediator of peroxisome proliferator action. , 1995, Mutation research.

[43]  C. Gerlinger,et al.  Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. , 1994, Atherosclerosis.

[44]  C. Hignite,et al.  HYPOLIPIDEMIC HEPATIC PEROXISOME PROLIFERATORS FORM A NOVEL CLASS OF CHEMICAL CARCINOGENS , 1980 .